NCATS Funding Opportunity: Pfizer’s Center for Therapeutic Innovation Program
Posted by: Crystal Williams on: October 3, 2018 | Print This Page
Proposal Portal Now Open; Pre-Proposals Due November 2
NCATS announces an opportunity for NIH intramural researchers to submit proposals to collaborate with Pfizer’s Centers for Therapeutic Innovation (CTI).
Pfizer’s CTI program, which is managed by NCATS, pairs NIH intramural researchers with Pfizer resources to pursue scientific and medical advances through joint therapeutic development. Goals include identifying biologic compounds with activity in a pathway or target of interest to both an NIH intramural researcher and Pfizer and moving the compounds into the clinic to test them. Areas of interest to Pfizer include cancer, autoimmunity/inflammation, metabolic diseases and rare diseases. View details about these therapeutic areas of interest at https://ncats.nih.gov/cti/therapeutic-areas-interest.
Pre-proposals are due to the investigator’s NIH Institute or Center’s technology transfer office by Nov. 2, 2018. Technology transfer staff must submit the pre-proposals by Nov. 9, 2018, via the Pfizer CTI submission portal at https://proposalportal.pfizercti.com/.
Tenured or tenure-tracked NIH intramural researchers interested in the program can meet with Pfizer CTI staff to discuss non-confidential pre-proposal ideas on Wednesday, Oct. 17, 2018, from noon to 4 p.m. in Building 10, Room 2-3330. To schedule a time, contact Pfizer CTI Representative Nader Halim, Ph.D., at firstname.lastname@example.org and copy email@example.com.
- Find out how to apply.
- View the therapeutic areas of interest to Pfizer.
- See frequently asked questions.
- Learn more about Pfizer’s CTI for NIH researchers